Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation

Chiaki Nakaseko, Shinichi Ozawa, Emiko Sakaida, Miwa Sakai, Yoshinobu Kanda, Kumi Oshima, Mineo Kurokawa, Satoshi Takahashi, Jun Ooi, Takayuki Shimizu, Akira Yokota, Fumiaki Yoshiba, Katsumichi Fujimaki, Heiwa Kanamori, Rika Sakai, Takayuki Saitoh, Tohru Sakura, Atsuo Maruta, Hisashi Sakamaki, Shinichiro Okamoto

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Bronchiolitis obliterans (BO) after allogeneic stem cell transplantation (allo-SCT) is a late-onset, life-threatening respiratory complication that significantly reduces a patient's quality of life. We retrospectively analysed the incidence of and risk factors for BO in allo-SCT recipients. In 2087 patients who underwent allo-SCT between January 1994 and June 2005 and survived >90 days after transplantation, 57 patients developed BO with a 5-year cumulative incidence of 2.8%. The median time interval from transplantation to BO diagnosis was 335 days (range 83-907 days). The 5-year cumulative incidence of BO was 1.62% in bone marrow transplantation (BMT) from related donors, 3.83% in peripheral blood stem cell transplantation (PBSCT) from related donors (R-PBSCT), 2.91% in BMT from unrelated donors and 2.65% in unrelated cord blood transplantation. The incidence of BO after R-PBSCT was significantly higher than that after any other type of allo-SCT (p = 0.02). R-PBSCT (p = 0.019) and preceding chronic graft-versus-host disease (GVHD) (p < 0.001) were BO-associated risk factors. Overall 5-year survival of patients with BO from the time of diagnosis was 45.4%, significantly less than those without (77.5% from day 335, p < 0.001). R-PBSCT recipients with existent chronic GVHD have a high risk of developing BO, and need extensive care and repeated pulmonary function tests.

Original languageEnglish
Pages (from-to)375-382
Number of pages8
JournalInternational Journal of Hematology
Volume93
Issue number3
DOIs
Publication statusPublished - 2011 Mar

Fingerprint

Bronchiolitis Obliterans
Stem Cell Transplantation
Peripheral Blood Stem Cell Transplantation
Incidence
Transplantation
Graft vs Host Disease
Bone Marrow Transplantation
Tissue Donors
Unrelated Donors
Respiratory Function Tests
Fetal Blood
Quality of Life

Keywords

  • Bronchiolitis obliterans
  • Chronic GVHD
  • Late onset non-infectious pulmonary complications
  • PBSC

ASJC Scopus subject areas

  • Hematology

Cite this

Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. / Nakaseko, Chiaki; Ozawa, Shinichi; Sakaida, Emiko; Sakai, Miwa; Kanda, Yoshinobu; Oshima, Kumi; Kurokawa, Mineo; Takahashi, Satoshi; Ooi, Jun; Shimizu, Takayuki; Yokota, Akira; Yoshiba, Fumiaki; Fujimaki, Katsumichi; Kanamori, Heiwa; Sakai, Rika; Saitoh, Takayuki; Sakura, Tohru; Maruta, Atsuo; Sakamaki, Hisashi; Okamoto, Shinichiro.

In: International Journal of Hematology, Vol. 93, No. 3, 03.2011, p. 375-382.

Research output: Contribution to journalArticle

Nakaseko, C, Ozawa, S, Sakaida, E, Sakai, M, Kanda, Y, Oshima, K, Kurokawa, M, Takahashi, S, Ooi, J, Shimizu, T, Yokota, A, Yoshiba, F, Fujimaki, K, Kanamori, H, Sakai, R, Saitoh, T, Sakura, T, Maruta, A, Sakamaki, H & Okamoto, S 2011, 'Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation', International Journal of Hematology, vol. 93, no. 3, pp. 375-382. https://doi.org/10.1007/s12185-011-0809-8
Nakaseko, Chiaki ; Ozawa, Shinichi ; Sakaida, Emiko ; Sakai, Miwa ; Kanda, Yoshinobu ; Oshima, Kumi ; Kurokawa, Mineo ; Takahashi, Satoshi ; Ooi, Jun ; Shimizu, Takayuki ; Yokota, Akira ; Yoshiba, Fumiaki ; Fujimaki, Katsumichi ; Kanamori, Heiwa ; Sakai, Rika ; Saitoh, Takayuki ; Sakura, Tohru ; Maruta, Atsuo ; Sakamaki, Hisashi ; Okamoto, Shinichiro. / Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. In: International Journal of Hematology. 2011 ; Vol. 93, No. 3. pp. 375-382.
@article{e23e7381fb424948982b7b9ae89ba69d,
title = "Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation",
abstract = "Bronchiolitis obliterans (BO) after allogeneic stem cell transplantation (allo-SCT) is a late-onset, life-threatening respiratory complication that significantly reduces a patient's quality of life. We retrospectively analysed the incidence of and risk factors for BO in allo-SCT recipients. In 2087 patients who underwent allo-SCT between January 1994 and June 2005 and survived >90 days after transplantation, 57 patients developed BO with a 5-year cumulative incidence of 2.8{\%}. The median time interval from transplantation to BO diagnosis was 335 days (range 83-907 days). The 5-year cumulative incidence of BO was 1.62{\%} in bone marrow transplantation (BMT) from related donors, 3.83{\%} in peripheral blood stem cell transplantation (PBSCT) from related donors (R-PBSCT), 2.91{\%} in BMT from unrelated donors and 2.65{\%} in unrelated cord blood transplantation. The incidence of BO after R-PBSCT was significantly higher than that after any other type of allo-SCT (p = 0.02). R-PBSCT (p = 0.019) and preceding chronic graft-versus-host disease (GVHD) (p < 0.001) were BO-associated risk factors. Overall 5-year survival of patients with BO from the time of diagnosis was 45.4{\%}, significantly less than those without (77.5{\%} from day 335, p < 0.001). R-PBSCT recipients with existent chronic GVHD have a high risk of developing BO, and need extensive care and repeated pulmonary function tests.",
keywords = "Bronchiolitis obliterans, Chronic GVHD, Late onset non-infectious pulmonary complications, PBSC",
author = "Chiaki Nakaseko and Shinichi Ozawa and Emiko Sakaida and Miwa Sakai and Yoshinobu Kanda and Kumi Oshima and Mineo Kurokawa and Satoshi Takahashi and Jun Ooi and Takayuki Shimizu and Akira Yokota and Fumiaki Yoshiba and Katsumichi Fujimaki and Heiwa Kanamori and Rika Sakai and Takayuki Saitoh and Tohru Sakura and Atsuo Maruta and Hisashi Sakamaki and Shinichiro Okamoto",
year = "2011",
month = "3",
doi = "10.1007/s12185-011-0809-8",
language = "English",
volume = "93",
pages = "375--382",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation

AU - Nakaseko, Chiaki

AU - Ozawa, Shinichi

AU - Sakaida, Emiko

AU - Sakai, Miwa

AU - Kanda, Yoshinobu

AU - Oshima, Kumi

AU - Kurokawa, Mineo

AU - Takahashi, Satoshi

AU - Ooi, Jun

AU - Shimizu, Takayuki

AU - Yokota, Akira

AU - Yoshiba, Fumiaki

AU - Fujimaki, Katsumichi

AU - Kanamori, Heiwa

AU - Sakai, Rika

AU - Saitoh, Takayuki

AU - Sakura, Tohru

AU - Maruta, Atsuo

AU - Sakamaki, Hisashi

AU - Okamoto, Shinichiro

PY - 2011/3

Y1 - 2011/3

N2 - Bronchiolitis obliterans (BO) after allogeneic stem cell transplantation (allo-SCT) is a late-onset, life-threatening respiratory complication that significantly reduces a patient's quality of life. We retrospectively analysed the incidence of and risk factors for BO in allo-SCT recipients. In 2087 patients who underwent allo-SCT between January 1994 and June 2005 and survived >90 days after transplantation, 57 patients developed BO with a 5-year cumulative incidence of 2.8%. The median time interval from transplantation to BO diagnosis was 335 days (range 83-907 days). The 5-year cumulative incidence of BO was 1.62% in bone marrow transplantation (BMT) from related donors, 3.83% in peripheral blood stem cell transplantation (PBSCT) from related donors (R-PBSCT), 2.91% in BMT from unrelated donors and 2.65% in unrelated cord blood transplantation. The incidence of BO after R-PBSCT was significantly higher than that after any other type of allo-SCT (p = 0.02). R-PBSCT (p = 0.019) and preceding chronic graft-versus-host disease (GVHD) (p < 0.001) were BO-associated risk factors. Overall 5-year survival of patients with BO from the time of diagnosis was 45.4%, significantly less than those without (77.5% from day 335, p < 0.001). R-PBSCT recipients with existent chronic GVHD have a high risk of developing BO, and need extensive care and repeated pulmonary function tests.

AB - Bronchiolitis obliterans (BO) after allogeneic stem cell transplantation (allo-SCT) is a late-onset, life-threatening respiratory complication that significantly reduces a patient's quality of life. We retrospectively analysed the incidence of and risk factors for BO in allo-SCT recipients. In 2087 patients who underwent allo-SCT between January 1994 and June 2005 and survived >90 days after transplantation, 57 patients developed BO with a 5-year cumulative incidence of 2.8%. The median time interval from transplantation to BO diagnosis was 335 days (range 83-907 days). The 5-year cumulative incidence of BO was 1.62% in bone marrow transplantation (BMT) from related donors, 3.83% in peripheral blood stem cell transplantation (PBSCT) from related donors (R-PBSCT), 2.91% in BMT from unrelated donors and 2.65% in unrelated cord blood transplantation. The incidence of BO after R-PBSCT was significantly higher than that after any other type of allo-SCT (p = 0.02). R-PBSCT (p = 0.019) and preceding chronic graft-versus-host disease (GVHD) (p < 0.001) were BO-associated risk factors. Overall 5-year survival of patients with BO from the time of diagnosis was 45.4%, significantly less than those without (77.5% from day 335, p < 0.001). R-PBSCT recipients with existent chronic GVHD have a high risk of developing BO, and need extensive care and repeated pulmonary function tests.

KW - Bronchiolitis obliterans

KW - Chronic GVHD

KW - Late onset non-infectious pulmonary complications

KW - PBSC

UR - http://www.scopus.com/inward/record.url?scp=79955814842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955814842&partnerID=8YFLogxK

U2 - 10.1007/s12185-011-0809-8

DO - 10.1007/s12185-011-0809-8

M3 - Article

VL - 93

SP - 375

EP - 382

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -